7.89
0.28 (3.68%)
| Previous Close | 7.61 |
| Open | 8.14 |
| Volume | 11,234 |
| Avg. Volume (3M) | 41,951 |
| Market Cap | 109,094,240 |
| Price / Earnings (TTM) | 17.53 |
| Price / Earnings (Forward) | 22.88 |
| Price / Sales | 1.91 |
| Price / Book | 20.23 |
| 52 Weeks Range | |
| Earnings Date | 16 Jul 2025 - 21 Jul 2025 |
| Profit Margin | 10.97% |
| Operating Margin (TTM) | 26.40% |
| Diluted EPS (TTM) | 0.450 |
| Quarterly Revenue Growth (YOY) | 41.80% |
| Total Debt/Equity (MRQ) | 117.70% |
| Current Ratio (MRQ) | 0.990 |
| Operating Cash Flow (TTM) | -1.30 M |
| Levered Free Cash Flow (TTM) | -3.45 M |
| Return on Assets (TTM) | 14.64% |
| Return on Equity (TTM) | 376.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Champions Oncology, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.63 |
|
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 25.85% |
| % Held by Institutions | 47.79% |
| 52 Weeks Range | ||
| Median | 12.00 (52.09%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 12 Mar 2025 | 12.00 (52.09%) | Buy | 9.55 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Apr 2025 | Announcement | Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House |
| 24 Apr 2025 | Announcement | Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine |
| 11 Mar 2025 | Announcement | Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million |
| 06 Mar 2025 | Announcement | Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025 |
| 18 Feb 2025 | Announcement | Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |